Evaxion (NASDAQ: EVAX) AGM backs 2025 report and Board, adds new director

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology™-powered vaccines, reported the results of its Annual General Meeting held at its offices in Denmark. The 2025 Annual Report was approved and all proposals from the Board of Directors were passed.

Shareholders re-elected Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda to the Board of Directors, and elected Jens Bitsch Nørhave as a new Board member. The company noted that minutes from the meeting are available on its website and reiterated its focus on AI-driven vaccine candidates in oncology and infectious diseases.

Key Terms

Annual General Meeting, AI-Immunology™, clinical-stage, forward-looking statements, +1 more

5 terms

Annual General Meeting financial

"Evaxion A/S ... held its Annual General Meeting today at the company’s offices."

AI-Immunology™ technical

"a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform"

ai-immunology™ is the use of artificial intelligence techniques to analyze immune system data and guide the discovery, design and testing of immune-based diagnostics, vaccines and therapies. It matters to investors because it can speed up research, reduce costs and reveal promising drug targets that traditional methods might miss—like using a powerful search engine to find a few needles in a vast haystack of biological signals—potentially increasing the chance and pace of commercial returns.

clinical-stage medical

"Evaxion A/S ... a clinical-stage TechBio company developing novel vaccines"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

forward-looking statements regulatory

"This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Annual Report on Form 20-F regulatory

"refer to the risk factors included in our most recent Annual Report on Form 20-F"

An annual report on Form 20-F is a standardized filing that foreign companies submit to the U.S. securities regulator to disclose their financial results, business operations, risks, and management’s discussion of performance. It matters to investors because it provides a complete, audited snapshot—like a company’s financial report card and shareholder letter combined—used to assess transparency, compare companies, and judge whether the stock’s price matches underlying business strengths and risks.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On April 16, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion concludes Annual General Meeting". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		Evaxion concludes Annual General Meeting

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: April 16, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

Evaxion concludes Annual General Meeting

COPENHAGEN, Denmark, April 16, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, held its Annual General Meeting today at the company’s offices.

The 2025 Annual Report was approved and the Board of Directors’ proposals passed.

Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda were re-elected to the Board of Directors. Jens Bitsch Nørhave was elected to the Board of Directors.

Minutes from the meeting can be found on our website.

Contact information

Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About

Evaxion Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options. 

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.

Forward-looking statement 

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, 2 including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.

FAQ

What did Evaxion A/S (EVAX) approve at its 2026 Annual General Meeting?

Evaxion A/S approved its 2025 Annual Report and passed all proposals submitted by the Board of Directors. These approvals confirm shareholder support for the company’s reported performance, governance decisions and ongoing strategy focused on AI-Immunology™-driven vaccine development.

Were there any changes to Evaxion A/S (EVAX) Board of Directors at the AGM?

Yes. Four existing directors were re-elected, and Jens Bitsch Nørhave was newly elected to the Board. Marianne Søgaard, Lars Holtug, Lars Aage Staal Wegner and Roberto Prego Pineda will continue serving, providing continuity alongside the new addition.

What kind of company is Evaxion A/S (EVAX) according to this filing?

Evaxion A/S is described as a clinical-stage TechBio company developing novel vaccines using its proprietary AI-Immunology™ platform. The platform applies artificial intelligence to decode immune responses and support vaccine candidates for cancer and infectious diseases.

Where can investors find the minutes from Evaxion A/S (EVAX) Annual General Meeting?

The company states that minutes from the Annual General Meeting are available on its website. Investors can review those minutes for detailed voting results, discussions, and formal resolutions adopted during the meeting beyond the high-level outcomes summarized here.

Does this Evaxion A/S (EVAX) update include any forward-looking statements?

Yes. The announcement includes forward-looking statements about development progress, financial condition, commercialization, partnerships and macroeconomic impacts. It also directs readers to risk factors in Evaxion’s most recent Form 20-F and other SEC filings for a fuller description of uncertainties.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 4.7 KB